Overview

Follistatin-344 is a 344-amino acid isoform of the native glycoprotein follistatin, engineered for targeted research applications. Follistatin is a potent endogenous inhibitor of multiple TGF-β superfamily members, most notably myostatin and activin A, which are primary negative regulators of skeletal muscle mass. Early 2000s research in mice demonstrated that follistatin-344 gene delivery could double muscular tissue mass, establishing it as one of the most powerful anabolic signaling modulators known.

Mechanism of Action

Follistatin-344 binds with high affinity to myostatin and activin A, preventing their interaction with activin type II receptors (ActRIIA/ActRIIB) and blocking downstream SMAD2/3 signaling that inhibits muscle growth. This disinhibition allows anabolic pathways (Akt/mTOR) to proceed uninhibited. The peptide also sequesters bone morphogenetic proteins (BMPs) and may interact with other TGF-β family members. By eliminating myostatin's brake on muscle protein synthesis, it enables significant hypertrophy and hyperplasia.

Potential Benefits

  • Near doubling of muscle mass in gene delivery animal models
  • Myostatin and activin neutralization enabling exceptional hypertrophy
  • Significant improvements in 6-minute walk test in sporadic inclusion body myositis clinical trial
  • Reduction in muscle fibrosis (32% in some models)
  • Potential bone density enhancement through BMP modulation
  • Hair follicle growth improvements (~13% in year-long studies)
  • Reduced liver fibrosis via activin pathway inhibition

Dosage Protocols

The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.

Typical Range50-200 mcg/dose, 1-3x/week
Beginner50-100 mcg twice weekly
Intermediate100-200 mcg twice weekly
Advanced200-300 mcg 3x/week (research protocols only)
Cycle Duration4-6 weeks maximum
Cycle Off8-12 weeks minimum

The biologically active isoform that inhibits myostatin and activin A/B. Injection into target muscle groups is commonly practiced for localized growth. Extended cycles risk muscle imbalances. Medical supervision essential.

Routes of Administration

Intramuscular Injection High

Local injection into target muscle produces localized muscle growth response; most common research approach

Subcutaneous Injection High

Systemic distribution; affects all muscle groups equally; less localized than IM

Stacking Protocols

Popular research stacks involving Follistatin-344:

Myostatin Inhibition Stack

Multi-pathway myostatin/activin inhibition for maximum muscle development

Follistatin-344 binds and neutralizes myostatin and activin; ACE-031 acts as a decoy receptor; IGF-1 LR3 simultaneously drives anabolic signaling.

Performance Enhancement Stack

Myostatin inhibition with GH axis activation for superior muscle growth

Complementary anabolic pathways; GH axis peptides drive nutrient partitioning and protein synthesis; Follistatin removes the myostatin brake on muscle growth.

Reconstitution

Typical Vial Size1mg, 2mg
BAC Water1-2ml per 1mg vial; some protocols use 0.6% acetic acid
StorageRefrigerate at 2-8°C after reconstitution; extremely sensitive to heat and agitation
Shelf Life14-21 days refrigerated; lyophilized at -20°C for long-term storage

Need exact syringe measurements?

Amino Acid Sequence

344 amino acid glycoprotein derived from the FST gene; full sequence in UniProt P19883

Side Effects & Safety

  • Potential dose-dependent cardiac, bone, and vascular effects
  • Theoretical risk of non-targeted tissue effects (endometrial, ovarian)
  • Nosebleeds observed in ACE-031 trials (related compound)
  • Long-term safety of myostatin blockade incompletely established

Synergistic Compounds

The following compounds have been studied alongside Follistatin-344 for potential complementary or synergistic effects:

Learn More

References & Further Reading

  • [object Object]
  • [object Object]
  • [object Object]

More Peptides in This Category